Newron Pharmaceuticals S.p.A. (FRA:NP5)

Market Cap	425.65M +125.3%
Revenue (ttm)	59.88M +759.1%
Net Income	25.33M
EPS	1.19
Shares Out	n/a
PE Ratio	16.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,250
Average Volume	2,616
Open	20.85
Previous Close	21.75
Day's Range	20.85 - 21.80
52-Week Range	5.91 - 33.55
Beta	n/a
RSI	37.79
Earnings Date	Mar 24, 2026

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NP5